177Lu-DOTA-2P(FAPI) therapy given 7 days post-MI significantly reduced myocardial fibrosis and improved cardiac function at 3 and 28 days without significant toxicity.
Does 177Lu-DOTA-2P(FAPI)2 reduce myocardial fibrosis and improve cardiac function in a post-myocardial infarction model?
A novel FAP-targeted radio-theranostic platform demonstrates potential for noninvasive imaging and targeted attenuation of post-infarction myocardial fibrosis.
Absolute Event Rate: 0% vs 0%
Excessive fibrosis drives adverse remodeling after myocardial infarction (MI), yet targeted theranostic strategies remain limited. To enable precise diagnosis and intervention, we developed a FAP-dimer-based imaging/therapeutic platform using 68Ga-DOTA-2P(FAPI)2 for noninvasive visualization of fibroblast activation and its therapeutic analogue 177Lu-DOTA-2P(FAPI)2 for radionuclide therapy. Cardiac function and fibrosis progression were assessed by echocardiography and histopathology, biosafety was evaluated via serum biochemistry and organ staining, and single-cell RNA sequencing (scRNA-seq) was performed to elucidate the underlying mechanisms. 68Ga-DOTA-2P(FAPI)2 demonstrated a high and specific uptake in early post-MI fibrotic regions. Therapeutic administration of 177Lu-DOTA-2P(FAPI)2 at day 7 significantly reduced myocardial fibrosis and improved cardiac function in both short- and long-term (3 and 28 days) evaluations. No significant toxicity was observed within 7 days post-treatment. scRNA-seq revealed selective depletion of activated fibroblasts and suppression of pro-inflammatory signaling in the infarct border zone, confirming the antifibrotic mechanism.
Liu et al. (Wed,) reported a other. 177Lu-DOTA-2P(FAPI) therapy given 7 days post-MI significantly reduced myocardial fibrosis and improved cardiac function at 3 and 28 days without significant toxicity.